Gastric and Gastroesophageal Junction Adenocarcinoma Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2019-2029

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$10995
Buy Report

Published: May 30, 2022 Report Code: GDHC245PIDR-ST

Select Item

The Gastric and Gastroesophageal Junction Adenocarcinoma (G/GEJAC) market size across the 8MM was valued at $1.12 billion in 2019 and is forecast to grow at a CAGR of more than 15% during 2019-2029. Growth of the market will be driven by the recent expansions of Opdivo and Keytruda into the first-line metastatic setting, further expansions for multiple agents across the 8MM, and the launches of nine pipeline agents.

G/GEJAC Market Outlook, 2019 ( $ Billion)

G/GEJAC Market Outlook

To gain more information on the G/GEJAC market forecast, download a free report sample

G/GEJAC Market Drivers

The major drivers of growth in the G/GEJAC market across the 8MM over the forecast period include multiple label expansions for Bristol Myers Squibb’s (BMS’) Opdivo (nivolumab), increased adoption of expensive immunotherapies in the first-line and adjuvant settings, the approval and launch of premium-priced therapeutics in the 8MM, and the label expansions for Merck & Co.’s Keytruda (pembrolizumab) and AstraZeneca/Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) that will result in greater adoption of more expensive combinatorial regimens.

G/GEJAC Market Segmentation by Class

The key classes in the G/GEJAC  market are Generic Chemotherapies, Branded Chemotherapies, Targeted Therapies, and Immunotherapies. In 2021, Targeted Therapies were the leading class.

G/GEJAC Market Analysis, by Class, 2021 (%)

G/GEJAC Market Analysis, by Class

For more G/GEJAC class insights, download a free report sample

G/GEJAC Market - Competitive Landscape

Some of the leading players in the G/GEJAC market are Bristol Myers Squibb, Merck & Co, AstraZeneca, Daiichi Sankyo, F. Hoffmann-La Roche, Eli Lilly, BeiGene, Astellas, Zymeworks, and Seagen.

G/GEJAC Market Report Overview

Market Size (2019) $1.12 billion
CAGR (2019 – 2029) >15%
Forecast period 2020-2029
Key Classes Generic Chemotherapies, Branded Chemotherapies, Targeted Therapies, and Immunotherapies
Leading Players Bristol Myers Squibb, Merck & Co, AstraZeneca, Daiichi Sankyo, F. Hoffmann-La Roche, Eli Lilly, BeiGene, Astellas, Zymeworks, and Seagen

G/GEJAC Market Classes Outlook (Value, $ Billion, 2019-2029)

  • Generic Chemotherapies
  • Branded Chemotherapies
  • Targeted Therapies
  • Immunotherapies

Scope

This report provides

  • Overview of G/GEJAC including epidemiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.

  • Topline G/GEJAC market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.

  • Key topics including current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting G/GEJAC therapeutics sales in the 8MM.

  • Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs (Phase II-III).

  • Analysis of the current and future market competition in the global G/GEJAC therapeutics market. Insightful review of the key industry drivers and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

Reasons to Buy

The report will enable you to:

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

  • Develop business strategies by understanding the trends shaping and driving the global G/GEJAC therapeutics market.

  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global G/GEJAC market in the future.

  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

  • Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.

  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Bristol Myers Squibb
Merck & Co
AstraZeneca
Daiichi Sankyo
F. Hoffmann-La Roche
Eli Lilly
BeiGene
Astellas
Zymeworks
Seagen
LintonPharm
ALX Oncology
Amgen
Zai Lab
Merck Sharp & Dohme Corp
ArQule Inc
RemeGen Co Ltd
Novartis Pharma AG
EQRx Inc
CM Life Sciences III Inc
Gilead Sciences Inc
Pionyr Immunotherapeutics Inc
CStone Pharmaceuticals Co Ltd
ABPro Bio Co Ltd
Abpro Corp
Flame Biosciences Inc
Novarock Biotherapeutics Limited
Sagard Holdings ULC
AnaptysBio Inc
Healthcare Royalty Partners LP
ADC Therapeutics SA

Table of Contents

| Contents

| List of Tables

| List of Figures

| About GlobalData

1 Gastric and Gastroesophageal Junction Adenocarcinoma: Executive Summary – Updated May 2022, based on events up to May 30, 2022

1.1 Large Market Growth Forecast for the G/GEJAC Market During 2019–2029

1.2 BMS Set to Take Market-Leading Position

1.3 The Level of Unmet Need in the G/GEJAC Market is Set to Remain High

1.4 Increasing Interest in Developing Therapies for Niche Populations

1.5 Multiple Novel Therapies Set to Launch in Metastatic and Adjuvant Settings

1.6 What Do Physicians Think?

2 Introduction – Updated May 2022, based on events up to May 30, 2022

2.1 Catalyst – Market-Impacting Events Shaping Forecast Changes

2.2 Related Reports

2.3 Upcoming Reports

3 Disease Overview

3.1 Etiology and Pathophysiology

3.1.1 Etiology

3.1.2 Pathophysiology

3.2 Classification or Staging Systems

4 Epidemiology

4.1 Disease Background

4.2 Risk Factors and Comorbidities

4.3 Global and Historical Trends

4.3.1 8MM, Trends in the Diagnosed Incidence

4.4 Forecast Methodology

4.4.1 Sources

4.4.2 Forecast Assumptions and Methods

4.5 Epidemiological Forecast for Gastric Cancer (2019–2029)

4.5.1 Diagnosed Incident Cases of Gastric Cancer

4.5.2 Age-Specific Diagnosed Incident Cases of Gastric Cancer

4.5.3 Sex-Specific Diagnosed Incident Cases of Gastric Cancer

4.5.4 Five-Year Diagnosed Prevalent Cases of Gastric Cancer

4.5.5 Diagnosed Incident Cases of Gastric Cancer by Stage at Diagnosis

4.5.6 Diagnosed Incident Cases of Gastric Cancer with HER2 Overexpression

4.5.7 Diagnosed Incident Cases of Gastric Cancer with PD-L1 Expression

4.5.8 Diagnosed Incident Cases of Gastric Cancer with MSI

4.5.9 Diagnosed Incident Cases of Gastric Cancer with NTRK Gene Fusions

4.5.10 Diagnosed Incident Cases of GEJ Cancer

4.5.11 Diagnosed Incident Cases of Gastric Cancer, Excluding GEJ Cancer

4.5.12 Diagnosed Incident Cases of Gastric Adenocarcinoma

4.6 Discussion

4.6.1 Epidemiological Forecast Insight

4.6.2 COVID-19 Impact

4.6.3 Limitations of the Analysis

4.6.4 Strengths of the Analysis

5 Disease Management – Updated May 2022, based on events up to May 30, 2022

5.1 Diagnosis and Treatment Overview

5.2 US

5.3 Europe

5.4 Japan

5.5 South Korea

5.6 KOL Insights on Disease Management

6 Competitive Assessment – Updated May 2022, based on events up to May 30, 2022

6.1 Overview

7 Unmet Needs and Opportunity Assessment – Updated May 2022, based on events up to May 30, 2022

7.1 Overview

7.2 Novel Drugs to Address Stage IV G/GEJAC Patients

7.3 Lack of Treatment Options for Patients with Stage II–III G/GEJAC in the Adjuvant/Neoadjuvant Setting

7.4 Demanding Evaluation of Cost-Effectiveness Impacting Approval and Reimbursement Across the 8MM

7.5 Disparity in Adoption of Nationwide Screening Programs Hinders Early-Stage Disease Diagnosis in the US and 5EU

8 R&D Strategies – Updated May 2022, based on events up to May 30, 2022

8.1 Overview

8.1.1 The Development of HER2-Targeting Therapies with Novel MOAs

8.1.2 Investigation of Novel Immunotherapy Targets and Combinations with Targeted Agents

8.1.3 The Development of Novel Targets for Specific Populations

8.2 Clinical Trials Design

8.2.1 Use of Appropriate Agents in Comparator Arm in Trials

8.2.2 Use of Preferred Chemotherapy Regimens in Combination Treatment

9 Pipeline Assessment – Updated May 2022, based on events up to May 30, 2022

9.1 Overview

9.2 Promising Drugs in Clinical Development

10 Pipeline Valuation Analysis – Updated May 2022, based on events up to May 30, 2022

10.1 Overview

10.2 Competitive Assessment.

11 Current and Future Players – Updated May 2022, based on events up to May 30, 2022

11.1 Overview

11.2 Deal-Making Trends

12 Market Outlook – Updated May 2022, based on events up to May 30, 2022

12.1 Global Markets

12.1.1 Forecast

12.1.2 Drivers and Barriers – Global Issues

12.2 US

12.2.1 Forecast

12.2.2 Key Events

12.2.3 Drivers and Barriers

12.3 5EU

12.3.1 Forecast

12.3.2 Key Events

12.3.3 Drivers and Barriers

12.4 Japan

12.4.1 Forecast

12.4.2 Key Events

12.4.3 Drivers and Barriers

12.5 South Korea

12.5.1 Forecast

12.5.2 Key Events

12.5.3 Drivers and Barriers

13 Appendix

13.1 Bibliography

13.2 Abbreviations

13.3 Methodology

13.3.1 Forecasting Methodology

13.4 Primary Research – KOLs Interviewed for This Report

13.5 Primary Research – Prescriber Survey

13.6 About the Authors

13.6.1 Analyst

13.6.2 Managing Analyst

13.6.3 Epidemiologist

13.6.4 Vice President of Disease Analysis and Intelligence

13.6.5 Global Head and EVP of Healthcare Operations and Strategy

| Contact Us

Table

Table 1: G/GEJAC: Key Metrics in the 8MM

Table 2: Stage Definitions for Gastric Cancer

Table 3: Risk Factors for Gastric Cancer

Table 4: Treatment Guidelines for G/GEJAC

Table 5: Generic Chemotherapy Regimens Indicated for Gastric Cancer

Table 6: Top 10 Deals by Value, 2018–21

Table 7: G/GEJAC Market – Global Drivers and Barriers, 2019–29

Table 8: Key Events Impacting Sales for G/GEJAC in the US, 2019–29

Table 9: G/GEJAC Market – Drivers and Barriers in the US, 2019–29

Table 10: Key Events Impacting Sales for G/GEJAC in the 5EU, 2019–29

Table 11: G/GEJAC Market – Drivers and Barriers in the 5EU, 2019–29

Table 12: Key Events Impacting Sales for G/GEJAC in Japan, 2019–29

Table 13: G/GEJAC Market – Drivers and Barriers in Japan, 2019–29

Table 14: Key Events Impacting Sales for G/GEJAC in South Korea, 2019–29

Table 15: G/GEJAC Market – Drivers and Barriers in South Korea, 2019–2029

Table 16: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

Figures

Figure 1: Global Sales Forecast by Country for G/GEJAC in 2019 and 2029

Figure 2: Analysis of the Company Portfolio Gap in G/GEJAC During the Forecast Period

Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to be Licensed for the Treatment of G/GEJAC in the Adjuvant/Neoadjuvant Setting During the Forecast Period

Figure 4: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to be Licensed for the Treatment of G/GEJAC in the HER2-Positive Setting During the Forecast Period

Figure 5: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to be Licensed for the Treatment of G/GEJAC in the HER2-Negative Setting During the Forecast Period

Figure 6: 8MM, Diagnosed Incidence of Gastric Cancer, Men, Ages ≥20 Years, 2009–2029, Cases Per 100,000 Population

Figure 7: 8MM, Diagnosed Incidence of Gastric Cancer, Women, Ages ≥20 Years, 2009–2029, Cases Per 100,000 Population

Figure 8: Sources Used and Not Used for Diagnosed Incident Cases of Gastric Cancer

Figure 9: Sources Used for Diagnosed Incident Cases of Gastric Cancer by Stage at Diagnosis

Figure 10: Sources Used for Five-Year Diagnosed Prevalent Cases of Gastric Cancer

Figure 11: Sources Used for Diagnosed Incident Cases of Gastric Cancer with HER2 Overexpression

Figure 12: Sources Used for Diagnosed Incident Cases of Gastric Cancer with PD-L1 Expression

Figure 13: Sources Used for Diagnosed Incident Cases of Gastric Cancer with MSI

Figure 14: Sources Used for Diagnosed Incident Cases of Gastric Cancer with NTRK Gene Fusions

Figure 15: Sources Used for Diagnosed Incident Cases of GEJ Cancer

Figure 16: Sources Used for Diagnosed Incident Cases of Gastric Cancer, excluding GEJ Cancer

Figure 17: Sources Used for Diagnosed Incident Cases of Gastric Adenocarcinoma

Figure 18: 8MM, Diagnosed Incident Cases of Gastric Cancer, Men and Women, Ages ≥20 Years, 2019

Figure 19: 8MM, Age-Specific Diagnosed Incident Cases of Gastric Cancer, Men and Women, Ages ≥20 Years, 2019

Figure 20: 8MM, Sex-Specific Diagnosed Incident Cases of Gastric Cancer, Men and Women, Ages ≥20 Years, 2019, N

Figure 21: 8MM, Five-Year Diagnosed Prevalent Cases of Gastric Cancer, Men and Women, Ages ≥20 Years, 2019

Figure 22: 8MM, Diagnosed Incident Cases of Gastric Cancer by Stage at Diagnosis, Men and Women, Ages ≥20 Years, 2019

Figure 23: 8MM, Diagnosed Incident Cases of Gastric Cancer with HER2 Overexpression, Men and Women, Ages ≥20 Years, 2019

Figure 24: 8MM, Diagnosed Incident Cases of Gastric Cancer with PD-L1 Expression, Men and Women, Ages ≥20 Years, 2019

Figure 25: 8MM, Diagnosed Incident Cases of Gastric Cancer with MSI, Men and Women, Ages ≥20 Years, 2019

Figure 26: 8MM, Diagnosed Incident Cases of Gastric Cancer with NTRK Gene Fusions, Men and Women, Ages ≥20 Years, 2019

Figure 27: 8MM, Diagnosed Incident Cases of GEJ Cancer, Men and Women, Ages ≥20 Years, 2019

Figure 28: 8MM, Diagnosed Incident Cases of Gastric Cancer, Excluding GEJ Cancer, Men and Women, Ages ≥20 Years, 2019

Figure 29: 8MM, Diagnosed Incident Cases of Gastric Adenocarcinoma, Men and Women, Ages ≥20 Years, 2019

Figure 30: Treatment for G/GEJAC Patients Based on HER2 Status

Figure 31: Unmet Needs and Opportunities in G/GEJAC

Figure 32: Overview of the Development Pipeline in G/GEJAC

Figure 33: Key Late-Stage Trials for the Promising Pipeline Agents that GlobalData Expects to Be Licensed for G/GEJAC in the 8MM During the Forecast Period

Figure 34: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC, Chemotherapy/Chemoradiation, in the Neoadjuvant/Adjuvant Setting

Figure 35: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC, Herceptin, in the HER2-Positive Metastatic Setting

Figure 36: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC, Chemotherapy, in the HER2-Negative Metastatic Setting

Figure 37: Analysis of the Company Portfolio Gap in G/GEJAC During the Forecast Period

Figure 38: Global (8MM) Sales Forecast by Country for G/GEJAC in 20191 and 2029

Figure 39: Sales Forecast by Class for G/GEJAC in the US in 2019 and 2029

Figure 40: Sales Forecast by Class for G/GEJAC in the 5EU in 2019 and 2021

Figure 41: Sales Forecast by Class for G/GEJAC in Japan in 2019 and 2029

Figure 42: Sales Forecast by Class for G/GEJAC in South Korea in 2019 and 2029

Frequently asked questions

Gastric and Gastroesophageal Junction Adenocarcinoma Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2019-2029 standard reports
Currency USD
$10,995

Can be used by individual purchaser only

Most Popular
$21,990

Can be shared by unlimited users within one corporate location e.g. a regional office

$32,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Oncology reports
Pharmaceuticals
New
Cell and Gene Therapies in Ophthalmology - Disease Overview, Treatment…
$6,995 | March 2024
Pharmaceuticals
New
Clinical Trials Scorecard for Investigations in 2023
$695 | March 2024
Pharmaceuticals
New
Atopic Dermatitis (Atopic Eczema) Clinical Trial Analysis by Phase, Trial…
$2,500 | March 2024
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Gastric and Gastroesophageal Junction Adenocarcinoma Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2019-2029 in real time.

  • Access a live Gastric and Gastroesophageal Junction Adenocarcinoma Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2019-2029 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more